BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3317352)

  • 1. Immunogenicity and tolerance of a yeast-derived hepatitis B vaccine in homosexual men.
    Prinsen H; Goilav C; Safary A; André FE; Piot P
    Postgrad Med J; 1987; 63 Suppl 2():147-9. PubMed ID: 3317352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active immunization against hepatitis B: immunogenicity of a recombinant DNA vaccine in females, heterosexual and homosexual males.
    Laukamm-Josten U; von Laer G; Feldmeier H; Bienzle U; Uy A; Thomssen R; Guggenmoos-Holzmann I
    Postgrad Med J; 1987; 63 Suppl 2():143-6. PubMed ID: 3317351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a yeast-derived hepatitis B vaccine (Engerix-B) in healthy young adults.
    Crovari P; Crovari PC; Petrilli RC; Icardi GC; Bonanni P
    Postgrad Med J; 1987; 63 Suppl 2():161-4. PubMed ID: 3317356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a recombinant DNA hepatitis B vaccine in neonates.
    Meheus A; Alisjahbana A; Vranckx R; Sukadi A; Usman A; Ngantung W; Sugita E; Safary A; André F; Reniers J
    Postgrad Med J; 1987; 63 Suppl 2():139-41. PubMed ID: 3317350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients.
    Bruguera M; Cremades M; Mayor A; Sánchez Tapias JM; Rodés J
    Postgrad Med J; 1987; 63 Suppl 2():155-8. PubMed ID: 3317354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactogenicity and immunogenicity of a recombinant hepatitis B vaccine compared with a plasma-derived vaccine in young adults.
    Just M; Berger R; Just V
    Postgrad Med J; 1987; 63 Suppl 2():121-3. PubMed ID: 3317346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yeast-derived hepatitis B vaccine in thalassaemic patients: a preliminary report.
    Giammanco G; De Grandi V; Pignato S; Dolci C; Congia M; Pisu C; De Virgiliis S
    Postgrad Med J; 1987; 63 Suppl 2():151-4. PubMed ID: 3317353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a recombinant yeast-derived hepatitis B vaccine in healthy adults.
    Scheiermann N; Gesemann KM; Kreuzfelder E; Paar D
    Postgrad Med J; 1987; 63 Suppl 2():115-9. PubMed ID: 3317345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity and immunogenicity of different lots of a yeast-derived hepatitis B vaccine.
    Wiedermann G; Ambrosch F; Kremsner P; Kunz C; Hauser P; Simoen E; André F; Safary A
    Postgrad Med J; 1987; 63 Suppl 2():109-13. PubMed ID: 3317344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of yeast-derived hepatitis B vaccines in young adults.
    Bergamini F; Zanetti A
    Postgrad Med J; 1987; 63 Suppl 2():137-8. PubMed ID: 3317349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects.
    Ambrosch F; Frisch-Niggemeyer W; Kremsner P; Kunz C; André F; Safary A; Wiedermann G
    Postgrad Med J; 1987; 63 Suppl 2():129-35. PubMed ID: 3317348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers.
    Goudeau A; Denis F; Mounier M; Dubois F; Klein J; Godefroy A; Ballet M; Mountij A
    Postgrad Med J; 1987; 63 Suppl 2():125-8. PubMed ID: 3317347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination of newborns of HBsAg-positive carrier mothers with a recombinant DNA hepatitis B vaccine.
    Cadranel S; Zeghlache S; Fernandez S; Safary A; André F
    Postgrad Med J; 1987; 63 Suppl 2(736):159-60. PubMed ID: 3317355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine.
    André FE; Safary A
    Postgrad Med J; 1987; 63 Suppl 2():169-77. PubMed ID: 3317357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protection of chimpanzees against hepatitis B viral infection using a recombinant yeast-derived hepatitis B surface antigen.
    Schellekens H; de Reus A; Peetermans JH; van Eerd PA
    Postgrad Med J; 1987; 63 Suppl 2():93-6. PubMed ID: 3317363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of a new recombinant DNA hepatitis B vaccine.
    Safary A; André F
    Postgrad Med J; 1987; 63 Suppl 2():105-7. PubMed ID: 3317343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth.
    Jafarzadeh A; Montazerifar SJ
    J Ayub Med Coll Abbottabad; 2006; 18(4):4-9. PubMed ID: 17591001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of two dosages of recombinant hepatitis B vaccine in healthy adolescents in India.
    Velu V; Nandakumar S; Shanmugam S; Shankar EM; Thangavel S; Kulkarni PS; Thyagarajan SP
    Pediatr Infect Dis J; 2007 Nov; 26(11):1038-41. PubMed ID: 17984812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of hepatitis B in children in a high risk New Zealand community, and control using recombinant DNA vaccine.
    Milne A; Heydon JL; Hindle RC; Pearce NE
    N Z Med J; 1989 Apr; 102(866):182-4. PubMed ID: 2523525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.